Physician profile
Beth A Cochran
NPI 1891995361
$2,250.47
in general payments reported to CMS, 2019-2025
30 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $545 · 2021: $482 · 2022: $77.30 · 2023: $154 · 2024: $174 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $630 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $630.07 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $378.68 | 2019-2025 | Zepbound, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $229.10 | 2020-2025 | Trintellix |
| Glaxosmithkline, LLC. | $211.23 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $176.53 | 2019-2025 | Wegovy |
| Radius Health, INC. | $158.67 | 2019-2025 | Tymlos |
| Biohaven Pharmaceuticals, INC. | $154.42 | 2020-2021 | |
| Upsher-Smith Laboratories LLC | $98.47 | 2020 | |
| Astellas Pharma US INC | $97.96 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $92.25 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $90.32 | 2019-2025 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $70.68 | 2022-2024 | Rexulti |
| Sumitomo Pharma America, INC. | $63.49 | 2025 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $53.57 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $46.67 | 2020 | |
| Pfizer INC. | $44.68 | 2023-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.87 | 2025 | Caplyta |
| Lundbeck LLC | $29.34 | 2025 | Rexulti |
| Allergan, INC. | $28.59 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.23 | 2024 | |
| Daiichi Sankyo INC. | $18.89 | 2024 | Injectafer |
| Inspire Medical Systems, INC. | $18.40 | 2025 | Inspire |
| Axsome Therapeutics, INC. | $18.31 | 2025 | Auvelity |
| Exact Sciences Corporation | $18.02 | 2025 | The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $16.81 | 2025 | |
| Merck Sharp & Dohme LLC | $15.68 | 2022 | |
| Vanda Pharmaceuticals INC. | $13.90 | 2024 | Fanapt |
| Aytu Biopharma, INC. | $13.05 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.01 | 2019 | |
| Nabriva Therapeutics, Plc | $12.97 | 2021 | |
| Avion Pharmaceuticals | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Cochran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.